secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-008072
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M
--------------------------------------------------------------------------------

- Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.
- Company may offer and sell up to $250 million of common shares at-the-market on Nasdaq.
- Sales agents Jefferies and Stifel will receive up to 3.0% commission on gross proceeds.
- No minimum obligation to sell; program may be terminated by either party upon written notice.
- Shares sold under existing shelf registration statement (File No. 333-260010) and prospectus supplement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/0001564590-22-008072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/xene-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer